##plugins.themes.bootstrap3.article.main##

Cheng Chang Wenjie Yu Yuguang Fan Fengkun Cai Shen Lu Jiao Jiao Zhiguo Liu Chenlu Wang Yujie Fu

Abstract

Alzheimer's disease (AD) is a major public health concern due to its widespread prevalence and limited effective treatments, highlighting the urgent need for innovative therapies. This study explores the therapeutic potential of Phacellanthus tubiflorus Sieb. et Zucc. (P. tubiflorus), a traditional Chinese medicine, as a potential source of neuroprotective agents. Systematically phytochemical analysis, employing UPLC-Q-TOF/MS, identified 1,536 compounds within P. tubiflorus including a notable abundance of Magnoloside D, Acteoside, and Cordycepin. Network pharmacology analyses, integrated with molecular docking studies, predicted a convergence between P. tubiflorus-derived compounds and central regulators of AD pathophysiology, notably SRC proto-oncogene (SRC), Tumor necrosis factor (TNF), AKT Serine/Threonine Kinase 1 (AKT1), Interleukin 1 Beta (IL-1B), and Interleukin 6 (IL-6). Enrichment analyses further implicated these interactions in key biological processes and signaling pathways, including neuroactive ligand-receptor interaction, cAMP signaling pathway, PI3k-Akt signaling pathway, all of which are dysregulated in AD. Importantly, these in silico predictions were substantiated by in vitro experiments using an Aβ1–42-challenged SH-SY5Y cell model, demonstrating that Magnoloside D can attenuate neuroinflammatory responses and modulate post-translational phosphorylation. These findings provide mechanistic insights into the potential therapeutic effects of P. tubiflorus and highlights its promise as a novel avenue for AD intervention.

Downloads

Download data is not yet available.

##plugins.themes.bootstrap3.article.details##

Section
Articles